TG 02

Drug Profile

TG 02

Alternative Names: SB 1317; TG02

Latest Information Update: 19 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator S*BIO
  • Developer European Organisation for Research and Treatment of Cancer; National Cancer Institute (USA); S*BIO; Tragara Pharmaceuticals
  • Class Antineoplastics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Anaplastic astrocytoma; Glioblastoma
  • No development reported Cancer; Chronic lymphocytic leukaemia; Leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2018 Phase-I clinical trials in Anaplastic astrocytoma (In the elderly, Newly diagnosed, Combination therapy) in France, Switzerland (PO) (NCT03224104)
  • 01 Jun 2018 Phase-I clinical trials in Anaplastic astrocytoma (Monotherapy, In adults, Second-line therapy or greater) in Swaziland, France (PO) (NCT03224104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top